OPK News and Press, Opko Health Inc. From 06/28/23

2023-06-28 10:09:16 ET Gainers: Minerva Neurosciences ( NERV ) +51% . Regional Health Properties ( RHE ) +12% . Genfit ( GNFT ) +11% . RenovoRx ( RNXT ) +11% . OPKO Health ( OPK ) +5% . Losers: Cognition Therapeutics ( C...

New, longer-acting treatment offers option to reduce the frequency of injections for children with growth hormone deficiency from daily to once-weekly Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved...

2023-05-11 12:29:00 ET Summary In the first three months of 2023, the company posted $237.6 million in revenue, up 28.2% from the previous quarter. In addition to the Merck deal, OPKO received a $7 million payment from Vifor in Q1 2023, thanks to the German price approval for Raya...

2023-05-10 04:20:04 ET Summary OPKO Health has been a very poor performer in my portfolio. The company has had a lot of ups and downs over the last few years. It has taken a new go-to-market strategy as of late. It has license agreements for two of its drugs with Pfizer and Merck....

2023-05-08 15:20:06 ET The basic definition of penny stocks includes shares of public companies priced under $5. While some traders might argue that they are exclusive to the Over-The-Counter or “OTC exchange,” the truth is that numerous low-priced stocks can also be found on ...

2023-05-03 22:00:28 ET Image source: The Motley Fool. Opko Health (NASDAQ: OPK) Q1 2023 Earnings Call May 03, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Opko Health (OPK) Q1 2023 Earnings Call Transcript

2023-05-03 20:42:06 ET OPKO Health, Inc. (OPK) Q1 2023 Earnings Conference Call May 03, 2023, 16:30 ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman & CEO Elias Zerhouni - President & Vice Chairman Adam Logal - S...

2023-05-03 16:12:28 ET OPKO Health press release ( NASDAQ: OPK ): Q1 GAAP EPS of -$0.02 beats by $0.06 . Revenue of $237.6M (-27.8% Y/Y) beats by $44.25M . Pharmaceuticals: Revenue from products in the first quarter of 2023 increased to $40.4 million from $36.6...

MIAMI, May 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights include the following: OPKO Health’s ModeX Therapeutics, Inc. (ModeX) ent...

2023-04-26 00:15:28 ET Summary After bringing you the first quarter installment covering large-cap and mid-cap insider activity, today's article will focus on the latest insider activity within the small-cap range. We believe that insiders supply the market with high-quality infor...